| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 120.53% | Morgan Stanley | $46 → $6 | Downgrades | Overweight → Equal-Weight |
| 11/07/2023 | 120.53% | Stifel | → $6 | Downgrades | Buy → Hold |
| 11/07/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/10/2023 | 1958.29% | Stifel | → $56 | Reiterates | Buy → Buy |
| 10/10/2023 | 1811.27% | HC Wainwright & Co. | → $52 | Reiterates | Buy → Buy |
| 08/29/2023 | 1590.74% | Morgan Stanley | $45 → $46 | Maintains | Overweight |
| 08/11/2023 | 2178.83% | Credit Suisse | $63 → $62 | Maintains | Outperform |
| 08/11/2023 | 1811.27% | HC Wainwright & Co. | $54 → $52 | Maintains | Buy |
| 07/05/2023 | 2178.83% | Oppenheimer | $62 → $62 | Reiterates | Outperform → Outperform |
| 07/05/2023 | 1884.78% | HC Wainwright & Co. | $54 → $54 | Reiterates | Buy → Buy |
| 06/14/2023 | 2215.58% | Credit Suisse | → $63 | Assumes | → Outperform |
| 05/12/2023 | 1884.78% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 03/24/2023 | 2215.58% | Credit Suisse | → $63 | Reiterates | → Outperform |
| 03/24/2023 | 2178.83% | Oppenheimer | $65 → $62 | Maintains | Outperform |
| 03/21/2023 | 2730.15% | Wells Fargo | → $77 | Initiates Coverage On | → Overweight |
| 03/20/2023 | 1737.76% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/31/2023 | 1884.78% | Canaccord Genuity | $35 → $54 | Maintains | Buy |
| 01/27/2023 | 2105.31% | Oppenheimer | $55 → $60 | Maintains | Outperform |
| 12/19/2022 | 1737.76% | Goldman Sachs | → $50 | Initiates Coverage On | → Buy |
| 11/17/2022 | 1553.99% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
| 09/16/2022 | 1848.03% | Stifel | $45 → $53 | Maintains | Buy |
| 09/13/2022 | 1737.76% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
| 09/12/2022 | 2289.09% | Oppenheimer | $40 → $65 | Maintains | Outperform |
| 09/07/2022 | 1553.99% | Stifel | → $45 | Initiates Coverage On | → Buy |
| 09/01/2022 | 1223.19% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 08/17/2022 | 1186.43% | Canaccord Genuity | $30 → $35 | Maintains | Buy |
| 08/16/2022 | 2215.58% | Credit Suisse | $53 → $63 | Maintains | Outperform |
| 08/16/2022 | 1370.21% | Oppenheimer | $30 → $40 | Maintains | Outperform |
| 05/09/2022 | 1848.03% | Credit Suisse | → $53 | Initiates Coverage On | → Outperform |
| 03/31/2022 | 1002.66% | Canaccord Genuity | → $30 | Initiates Coverage On | → Buy |
| 02/01/2022 | 1002.66% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 11/15/2021 | 1737.76% | Evercore ISI Group | → $50 | Initiates Coverage On | → Outperform |
| 11/15/2021 | 1002.66% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 11/15/2021 | 1737.76% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
What is the target price for Ventyx Biosciences (VTYX)?
The latest price target for Ventyx Biosciences (NASDAQ: VTYX) was reported by Morgan Stanley on November 7, 2023. The analyst firm set a price target for $6.00 expecting VTYX to rise to within 12 months (a possible 120.53% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ventyx Biosciences (VTYX)?
The latest analyst rating for Ventyx Biosciences (NASDAQ: VTYX) was provided by Morgan Stanley, and Ventyx Biosciences downgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Ventyx Biosciences (VTYX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Ventyx Biosciences (VTYX) correct?
While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a downgraded with a price target of $46.00 to $6.00. The current price Ventyx Biosciences (VTYX) is trading at is $2.72, which is out of the analyst's predicted range.